|
ES517193A0
(es)
|
1981-11-10 |
1983-12-01 |
Wellcome Found |
Un procedimiento para la preparacion de nuevos derivados de imidazo (4,5-c)piridina.
|
|
US4847256A
(en)
|
1986-10-16 |
1989-07-11 |
American Cyanamid Company |
4,5-dihydro and 4,5,6,7-tetrahydropyrazolo(1,5-A)-pyrimidines
|
|
AU650953B2
(en)
|
1991-03-21 |
1994-07-07 |
Novartis Ag |
Inhaler
|
|
US5728536A
(en)
|
1993-07-29 |
1998-03-17 |
St. Jude Children's Research Hospital |
Jak kinases and regulation of Cytokine signal transduction
|
|
US6136595A
(en)
|
1993-07-29 |
2000-10-24 |
St. Jude Children's Research Hospital |
Jak kinases and regulations of cytokine signal transduction
|
|
US5543523A
(en)
|
1994-11-15 |
1996-08-06 |
Regents Of The University Of Minnesota |
Method and intermediates for the synthesis of korupensamines
|
|
US5705625A
(en)
|
1994-12-15 |
1998-01-06 |
The Johns Hopkins University School Of Medicine |
Nucleic Acid Encoding novel protein tyrosine kinase
|
|
US7070972B1
(en)
|
1995-01-13 |
2006-07-04 |
The United States Of America As Represented By The Department Of Health And Human Services |
Janus family kinases and identification of immune modulators
|
|
JPH11508583A
(ja)
|
1995-07-06 |
1999-07-27 |
ゼネカ・リミテッド |
ペプチド系のフィブロネクチン阻害薬
|
|
US6248713B1
(en)
|
1995-07-11 |
2001-06-19 |
Biogen, Inc. |
Cell adhesion inhibitors
|
|
US7091020B1
(en)
|
1995-12-05 |
2006-08-15 |
Incyte Corporation |
Human Jak2 kinase
|
|
ID18494A
(id)
|
1996-10-02 |
1998-04-16 |
Novartis Ag |
Turunan pirazola leburan dan proses pembuatannya
|
|
US6235741B1
(en)
|
1997-05-30 |
2001-05-22 |
Merck & Co., Inc. |
Angiogenesis inhibitors
|
|
FR2791562B1
(fr)
|
1999-03-29 |
2004-03-05 |
Oreal |
Composition tinctoriale contenant une pyrazolo-[1,5-a]- pyrimidine et une polyaminopyrimidine monocyclique a titre de bases d'oxydation et un coupleur, et procedes de teinture
|
|
YU25500A
(sh)
|
1999-05-11 |
2003-08-29 |
Pfizer Products Inc. |
Postupak za sintezu analoga nukleozida
|
|
US6841549B1
(en)
|
1999-07-02 |
2005-01-11 |
Eisai Co., Ltd. |
Condensed imidazole compounds and a therapeutic agent for diabetes mellitus
|
|
DE60007552T2
(de)
|
1999-12-10 |
2004-09-23 |
Pfizer Products Inc., Groton |
PYRROLO[2,3-d]PYRIMIDIN-VERBINDUNGEN ALS PROTEIN KINASEN HEMMER
|
|
GB0028383D0
(en)
|
2000-11-21 |
2001-01-03 |
Novartis Ag |
Organic compounds
|
|
EP1241176A1
(fr)
|
2001-03-16 |
2002-09-18 |
Pfizer Products Inc. |
Dérivés de purine pour le traitement de l'ischémie
|
|
DE60214428T2
(de)
|
2001-12-20 |
2007-09-20 |
Bayer Healthcare Ag |
1, 4-dihydro-1, 4-diphenylpyridin-derivate
|
|
US7662826B2
(en)
|
2002-04-23 |
2010-02-16 |
Shionogi & Co., Ltd. |
Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same
|
|
US8580782B2
(en)
|
2002-09-04 |
2013-11-12 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
|
|
US7161003B1
(en)
|
2002-09-04 |
2007-01-09 |
Schering Corporation |
Pyrazolopyrimidines as cyclin dependent kinase inhibitors
|
|
US7129239B2
(en)
|
2002-10-28 |
2006-10-31 |
Pfizer Inc. |
Purine compounds and uses thereof
|
|
CA2502429A1
(fr)
|
2002-10-31 |
2004-05-21 |
Amgen Inc. |
Agents anti-inflammatoires
|
|
AU2003299651A1
(en)
|
2002-12-11 |
2004-06-30 |
Merck And Co., Inc. |
Tyrosine kinase inhibitors
|
|
EP1615667A2
(fr)
|
2003-04-11 |
2006-01-18 |
Novo Nordisk A/S |
Therapie combinatoire utilisant un inhibiteur de 11beta-hydroxysteroide deshydrogenase de type 1 et agoniste du recepteur de glucocorticoides
|
|
US20070270408A1
(en)
|
2003-04-11 |
2007-11-22 |
Novo Nordisk A/S |
Pharmaceutical use of substituted pyrazolo[1,5-a]pyrimidines
|
|
WO2004089471A2
(fr)
|
2003-04-11 |
2004-10-21 |
Novo Nordisk A/S |
Utilisation pharmaceutique de pyrazolo[1,5-a]pyrimidines substituees
|
|
WO2004089416A2
(fr)
|
2003-04-11 |
2004-10-21 |
Novo Nordisk A/S |
Polytherapie utilisant un inhibiteur de type 1 de la 11beta-hydroxysteroide deshydrogenase et un agent hypotenseur dans le traitement du syndrome metabolique et des troubles et maladies associes
|
|
EP1643960A2
(fr)
|
2003-07-02 |
2006-04-12 |
Merck & Co., Inc. |
Derives arylsulfonamide
|
|
TWI372050B
(en)
|
2003-07-03 |
2012-09-11 |
Astex Therapeutics Ltd |
(morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
|
|
SE0302487D0
(sv)
|
2003-09-18 |
2003-09-18 |
Astrazeneca Ab |
Novel compounds
|
|
GB0329214D0
(en)
|
2003-12-17 |
2004-01-21 |
Glaxo Group Ltd |
Novel compounds
|
|
US7306631B2
(en)
|
2004-03-30 |
2007-12-11 |
The Procter & Gamble Company |
Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
|
|
CA2563305A1
(fr)
|
2004-04-09 |
2005-11-24 |
University Of South Florida |
Polytherapies pour le cancer et des angiopathies proliferantes
|
|
WO2005105803A2
(fr)
|
2004-04-28 |
2005-11-10 |
Cv Therapeutics, Inc. |
Antagonistes du recepteur de l'adenosine a1
|
|
JP2008504294A
(ja)
|
2004-06-25 |
2008-02-14 |
アムジエン・インコーポレーテツド |
サイトカイン介在疾患および他の疾患の治療において有用な縮合トリアゾールおよびインダゾール
|
|
AU2005304784B2
(en)
|
2004-11-04 |
2011-03-24 |
Vertex Pharmaceuticals Incorporated |
Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases
|
|
GB0502258D0
(en)
|
2005-02-03 |
2005-03-09 |
Argenta Discovery Ltd |
Compounds and their use
|
|
US20100216798A1
(en)
|
2005-07-29 |
2010-08-26 |
Astellas Pharma Inc |
Fused heterocycles as lck inhibitors
|
|
WO2007039797A1
(fr)
|
2005-10-03 |
2007-04-12 |
Pfizer Products Inc. |
Utilisation d'antagonistes du recepteur cannabinoide de type 1 pour traiter les inflammations et l'arthrite
|
|
AR056206A1
(es)
*
|
2005-10-06 |
2007-09-26 |
Schering Corp |
Pirazolpirimidinas como inhibidores de protein quinasas
|
|
TW200745128A
(en)
|
2005-10-06 |
2007-12-16 |
Schering Corp |
Pyrazolopyrimidines as protein kinase inhibitors
|
|
US8372851B2
(en)
|
2005-10-21 |
2013-02-12 |
Exelixis, Inc. |
Pyrazolo pyrimidines as casein kinase II (CK2) modulators
|
|
EP1963316A2
(fr)
|
2005-12-08 |
2008-09-03 |
Novartis AG |
Acides pyrazolo[1,5-a]pyridine-3-carboxyliques utilises en tant qu inhibiteurs de la ephb et vegfr2 kinase
|
|
US8541406B2
(en)
|
2006-02-07 |
2013-09-24 |
Nv Remynd |
Thiadiazole derivatives for the treatment of neurodegenerative diseases
|
|
TW200800997A
(en)
|
2006-03-22 |
2008-01-01 |
Astrazeneca Ab |
Chemical compounds
|
|
AR061793A1
(es)
|
2006-07-05 |
2008-09-24 |
Mitsubishi Tanabe Pharma Corp |
Compuesto de pirazolo[1,5-a] pirimidina y composicion farmaceutica
|
|
US8217177B2
(en)
|
2006-07-14 |
2012-07-10 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
|
PE20080403A1
(es)
|
2006-07-14 |
2008-04-25 |
Amgen Inc |
Derivados heterociclicos fusionados y metodos de uso
|
|
JP2010508315A
(ja)
|
2006-10-30 |
2010-03-18 |
ノバルティス アーゲー |
抗炎症剤としてのヘテロ環式化合物
|
|
CA2670083A1
(fr)
|
2006-11-20 |
2008-05-29 |
Alantos Pharmaceuticals Holding, Inc. |
Inhibiteurs de metalloprotease heterobicycliques
|
|
WO2009017954A1
(fr)
|
2007-08-01 |
2009-02-05 |
Phenomix Corporation |
Inhibiteurs de kinase jak2
|
|
US8716296B2
(en)
|
2007-10-12 |
2014-05-06 |
Ingenium Pharmaceuticals Gmbh |
Inhibitors of protein kinases
|
|
EP3912973A3
(fr)
|
2007-11-28 |
2022-02-16 |
Dana-Farber Cancer Institute, Inc. |
Inhibiteurs de myristate de bcr-abl à petite molécule et procédés d'utilisation
|
|
US8642660B2
(en)
|
2007-12-21 |
2014-02-04 |
The University Of Rochester |
Method for altering the lifespan of eukaryotic organisms
|
|
MX2010014005A
(es)
|
2008-06-20 |
2011-02-15 |
Genentech Inc |
Compuestos de triazolopiridina inhibidores de jak y los metodos.
|
|
WO2010019762A1
(fr)
|
2008-08-13 |
2010-02-18 |
Jenrin Discovery |
Composés de purine en tant que bloqueurs de récepteur aux cannabinoïdes
|
|
AU2009308675A1
(en)
|
2008-10-31 |
2010-05-06 |
Genentech, Inc. |
Pyrazolopyrimidine JAK inhibitor compounds and methods
|
|
WO2010063487A1
(fr)
|
2008-12-05 |
2010-06-10 |
Merz Pharma Gmbh & Co. Kgaa |
Pyrazolopyrimidines, procédé pour leur préparation et leur utilisation comme médicament
|
|
KR20110113197A
(ko)
|
2009-02-06 |
2011-10-14 |
오르토-맥닐-얀센 파마슈티칼스 인코포레이티드 |
감마 세크레타제 조절제로서의 신규 치환된 비사이클릭 헤테로사이클릭 화합물
|
|
TWI461425B
(zh)
|
2009-02-19 |
2014-11-21 |
Janssen Pharmaceuticals Inc |
作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
|
|
UA110324C2
(en)
*
|
2009-07-02 |
2015-12-25 |
Genentech Inc |
Jak inhibitory compounds based on pyrazolo pyrimidine
|
|
AR077468A1
(es)
|
2009-07-09 |
2011-08-31 |
Array Biopharma Inc |
Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
|
|
EP2491039A1
(fr)
|
2009-10-20 |
2012-08-29 |
Cellzome Limited |
Analogues d'hétérocyclyl pyrazolopyrimidine en tant qu'inhibiteurs de jak
|
|
MX2012010265A
(es)
|
2010-03-17 |
2012-10-01 |
Hoffmann La Roche |
Compuestos de imidazopiridina, composiciones y metodos de uso.
|
|
BR112012027803A2
(pt)
|
2010-04-30 |
2016-08-09 |
Cellzome Ltd |
compostos de pirazol como inibidores de jak
|
|
MX358682B
(es)
|
2010-07-13 |
2018-08-31 |
Hoffmann La Roche |
Derivados de pirazolo [1,5a]pirimidina y de tieno[3,2b] pirimidina como moduladores de la cinasa asociada al receptor de la interleucina 4 (irak4).
|
|
WO2012075393A2
(fr)
|
2010-12-02 |
2012-06-07 |
President And Fellows Of Harvard College |
Activateurs de la dégradation protéasomique et leurs utilisations
|
|
EP2688872A4
(fr)
*
|
2011-03-22 |
2014-08-27 |
Merck Sharp & Dohme |
Inhibiteurs de kinases associées aux récepteurs d'interleukine à base d'amidopyrazole
|
|
US8575336B2
(en)
|
2011-07-27 |
2013-11-05 |
Pfizer Limited |
Indazoles
|
|
ES2666353T3
(es)
|
2012-09-06 |
2018-05-04 |
Bristol-Myers Squibb Company |
Inhibidores de JAK3 de imidazopiridazina y su uso para el tratamiento de enfermedades inflamatorias y autoinmunitarias
|
|
US9409893B2
(en)
|
2012-11-09 |
2016-08-09 |
Jacobus Pharmaceutical Company, Inc. |
Heteroaryl derivatives and uses thereof
|
|
US20160166576A1
(en)
|
2013-07-11 |
2016-06-16 |
Merck Sharp & Dohme Corp. |
Substituted amidopyrazole inhibitors of interleukin receptor-associated kinases (irak-4)
|
|
CN105899505B
(zh)
|
2013-11-08 |
2018-08-28 |
武田药品工业株式会社 |
用于治疗自身免疫病症的吡唑
|
|
WO2015073267A1
(fr)
|
2013-11-15 |
2015-05-21 |
Calitor Sciences, Llc |
Composés hétéroaryle substitués et méthodes d'utilisation
|
|
MX2016015062A
(es)
*
|
2014-05-23 |
2017-02-27 |
Hoffmann La Roche |
Compuestos de 5-cloro-2-difluorometoxifenil pirazolopirimidina los cuales son inhibidores de janus cinasas (jak).
|
|
JO3701B1
(ar)
|
2014-05-23 |
2021-01-31 |
Regeneron Pharma |
مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
|
|
EP3145522B1
(fr)
|
2014-05-23 |
2020-12-23 |
Phibro Animal Health Corporation |
Combinaison, composition et méthode d'administration de la combinaison ou de la composition à des animaux
|
|
CN107001379B
(zh)
|
2014-11-06 |
2022-11-01 |
Bial研发投资股份有限公司 |
取代的吡唑并[1,5-a]嘧啶以及它们在治疗医学障碍中的用途
|
|
EP3268367B8
(fr)
|
2015-03-12 |
2022-11-16 |
Merck Sharp & Dohme LLC |
Carboxamides utilisés comme inhibiteurs de l'activité de l'irak4
|
|
EP3267996B1
(fr)
|
2015-03-12 |
2020-11-11 |
Merck Sharp & Dohme Corp. |
Inhibiteurs de l'activité d'irak4 à base de pyrazolopyrimidine
|
|
EP3268004B1
(fr)
|
2015-03-12 |
2019-12-18 |
Merck Sharp & Dohme Corp. |
Inhibiteurs de l'activité d'irak4 à base de pyrrolopyridazine
|
|
EP3268006B1
(fr)
|
2015-03-12 |
2020-01-08 |
Merck Sharp & Dohme Corp. |
Inhibiteurs de pyrrolotriazine de l'activité d'irak4
|
|
TW201720828A
(zh)
|
2015-11-23 |
2017-06-16 |
赫孚孟拉羅股份公司 |
治療性化合物及組合物以及其使用方法
|
|
EP3416967B1
(fr)
|
2016-02-18 |
2022-02-09 |
F. Hoffmann-La Roche AG |
Composés thérapeutiques, leurs compositions et méthodes d'utilisation
|
|
EP3562809B1
(fr)
|
2016-12-29 |
2021-06-09 |
F. Hoffmann-La Roche AG |
Composés pyrazolopyrimidine et leurs procédés d'utilisation
|
|
JP2020510061A
(ja)
|
2017-03-14 |
2020-04-02 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
ピラゾロクロロフェニル化合物、組成物及びその使用方法
|
|
TW201902896A
(zh)
*
|
2017-05-22 |
2019-01-16 |
瑞士商赫孚孟拉羅股份公司 |
治療化合物及組合物及其使用方法
|
|
WO2018215390A1
(fr)
|
2017-05-22 |
2018-11-29 |
F. Hoffmann-La Roche Ag |
Composés thérapeutiques, compositions et procédés d'utilisation associés
|